KaloBios' KB001 Antibody Shows Encouraging Safety And Activity In New Approach To Fighting Pseudomonas Infection In Cystic Fibrosis Patients
Originally posted in Cystic Fibrosis News From Medical News Today
Phase 1/2 clinical trial results with KB001, a Humaneered™, high-affinity antibody fragment under development by KaloBios Pharmaceuticals, Inc. in cystic fibrosis patients showed an acceptable safety profile as well as trends toward reducing tissue inflammation and clearance of the bacterium…
by Raelene
